(S)-Ceralasertib
Product Sizes
1 mg
£ POA
HY-19323A-1MG
50 mg
£ POA
HY-19323A-50MG
5 mg
£ POA
HY-19323A-5MG
100 mg
£ POA
HY-19323A-100MG
10 mg
£ POA
HY-19323A-10MG
10mM/1mL
£ POA
HY-19323A-10MM
About this Product
- SKU:
- HY-19323A
- Additional Names:
- (S)-AZD6738
- CAS Number:
- 1352226-87-9
- Extra Details:
- (S)-Ceralasertib ((S)-AZD6738) is the S-enantiomer of Ceralasertib (HY-19323). (S)-Ceralasertib is the inhibitor for ataxia telangiectasia mutated and rad3 related (ATR)[1].
- Molecular Weight:
- 412.51
- Purity:
- 99.97
- References:
- [1]By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215.|[2]Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907.|[3]Espinar L, et al., Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity. Nat Commun. 2024 Nov 12;15(1):9515.|[4]Olmedo-Pelayo J, et al. EWS:: FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism[J]. BioRxiv, 2023: 2023.05. 30.542894.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Cell Cycle/DNA Damage;PI3K/Akt/mTOR
